Published in J Mol Diagn on August 09, 2007
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol (2008) 2.61
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene (2008) 2.19
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02
Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn (2009) 1.72
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res (2008) 1.39
Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One (2013) 1.34
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer (2012) 1.13
Optimized allele-specific real-time PCR assays for the detection of common mutations in KRAS and BRAF. J Mol Diagn (2010) 1.12
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice. Br J Cancer (2013) 1.10
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep (2013) 1.01
Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc (2012) 1.00
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther (2015) 0.99
Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. Case Rep Oncol (2012) 0.93
Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther (2014) 0.92
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Mol Cancer Ther (2008) 0.91
Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci Rep (2012) 0.90
A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol (2014) 0.90
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One (2013) 0.90
A rapid and reliable test for BRCA1 and BRCA2 founder mutation analysis in paraffin tissue using pyrosequencing. J Mol Diagn (2009) 0.88
Phospho-ERK and AKT status, but not KRAS mutation status, are associated with outcomes in rectal cancer treated with chemoradiotherapy. Radiat Oncol (2011) 0.87
Distinct molecular features of different macroscopic subtypes of colorectal neoplasms. PLoS One (2014) 0.87
Automated universal BRAF state detection within the activation segment in skin metastases by pyrosequencing-based assay U-BRAF(V600). PLoS One (2013) 0.82
SKINOMICS: Transcriptional Profiling in Dermatology and Skin Biology. Curr Genomics (2012) 0.80
The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type. J Invest Dermatol (2013) 0.77
BRAF pyrosequencing analysis aided by a lookup table. Am J Clin Pathol (2014) 0.76
BRAFV600E immunopositive melanomas show low frequency of heterogeneity and association with epithelioid tumor cells: a STROBE-compliant article. Medicine (Baltimore) (2014) 0.76
CXCR4 pathway associated with family history of melanoma. Cancer Causes Control (2013) 0.76
Variations of BRAF mutant allele percentage in melanomas. BMC Cancer (2015) 0.75
(18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status. Br J Radiol (2016) 0.75
Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction? Br J Cancer (2014) 0.75
Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. Br J Cancer (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Guilty as charged: B-RAF is a human oncogene. Cancer Cell (2004) 4.97
V599EB-RAF is an oncogene in melanocytes. Cancer Res (2004) 4.49
Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res (2002) 4.46
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res (2001) 3.66
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res (2006) 3.32
BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet (2004) 2.75
High-resolution identification of chromosomal abnormalities using oligonucleotide arrays containing 116,204 SNPs. Am J Hum Genet (2005) 2.39
BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res (2004) 2.37
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res (2006) 2.31
Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res (1997) 2.11
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia (2006) 1.90
Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer (2004) 1.66
Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Hum Genet (2004) 1.64
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res (2005) 1.55
BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell (2003) 1.55
Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab (2004) 1.54
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. Oncogene (2004) 1.48
BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res (2006) 1.43
Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Mol Cell Probes (2004) 1.39
BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol (2006) 1.35
Absence of BRAF mutations in UV-protected mucosal melanomas. J Med Genet (2004) 1.32
Raf kinases: oncogenesis and drug discovery. Int J Cancer (2006) 1.25
BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol (2005) 0.97
Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J Cutan Pathol (2005) 0.90
Detection of BRAF mutations in colorectal tumours and peritoneal washings using a mismatch ligation assay. J Clin Pathol (2005) 0.79
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature (2009) 7.39
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell (2010) 6.47
A promoter-level mammalian expression atlas. Nature (2014) 6.25
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol (2008) 5.31
Cornelia de Lange syndrome is caused by mutations in NIPBL, the human homolog of Drosophila melanogaster Nipped-B. Nat Genet (2004) 5.19
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell (2008) 4.84
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther (2006) 4.57
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res (2006) 4.20
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature (2011) 4.07
Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res (2003) 4.03
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 3.65
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res (2004) 3.62
Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol (2003) 3.51
Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol (2004) 3.43
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
Transcriptional dysregulation in NIPBL and cohesin mutant human cells. PLoS Biol (2009) 2.89
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet (2009) 2.85
Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 2.81
Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest (2008) 2.73
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem (2002) 2.58
Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest (2010) 2.48
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet (2009) 2.47
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell (2013) 2.43
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Evolution of sleep quantity, sleep deprivation, mood disturbances, empathy, and burnout among interns. Acad Med (2006) 2.39
Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol (2013) 2.38
Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest (2005) 2.38
A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer (2006) 2.35
Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim (2006) 2.32
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Isolation of a novel population of multipotent adult stem cells from human hair follicles. Am J Pathol (2006) 2.13
Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res (2006) 2.12
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res (2010) 2.02
The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci (2005) 2.00
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res (2008) 1.99
KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol (2009) 1.97
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol (2010) 1.93
Transcribed enhancers lead waves of coordinated transcription in transitioning mammalian cells. Science (2015) 1.91
Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res (2007) 1.89
Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. Am J Pathol (2005) 1.88
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin Cancer Res (2011) 1.84
Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol (2005) 1.84
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res (2007) 1.81
Distinct genomic profiles in hereditary breast tumors identified by array-based comparative genomic hybridization. Cancer Res (2005) 1.80
Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res (2002) 1.78
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78